Implementing Pharmacogenetic Testing in Gastrointestinal Cancers (IMPACT-GI): Study Protocol for a Pragmatic Implementation Trial for Establishing DPYD and UGT1A1 Screening to Guide Chemotherapy Dosing

BACKGROUND: Fluoropyrimidines (fluorouracil [5-FU], capecitabine) and irinotecan are commonly prescribed chemotherapy agents for gastrointestinal (GI) malignancies. Pharmacogenetic (PGx) testing for germline DPYD and UGT1A1 variants associated with reduced enzyme activity holds the potential to iden...

Descripción completa

Detalles Bibliográficos
Autores principales: Varughese, Lisa A., Bhupathiraju, Madhuri, Hoffecker, Glenda, Terek, Shannon, Harr, Margaret, Hakonarson, Hakon, Cambareri, Christine, Marini, Jessica, Landgraf, Jeffrey, Chen, Jinbo, Kanter, Genevieve, Lau-Min, Kelsey S., Massa, Ryan C., Damjanov, Nevena, Reddy, Nandi J., Oyer, Randall A., Teitelbaum, Ursina R., Tuteja, Sony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295185/
https://www.ncbi.nlm.nih.gov/pubmed/35865463
http://dx.doi.org/10.3389/fonc.2022.859846

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295185/
https://www.ncbi.nlm.nih.gov/pubmed/35865463
http://dx.doi.org/10.3389/fonc.2022.859846

Ejemplares similares